OnKure Therapeutics (NASDAQ:OKUR – Free Report) – Investment analysts at Leerink Partnrs boosted their FY2025 earnings estimates for OnKure Therapeutics in a report issued on Wednesday, February 5th. Leerink Partnrs analyst A. Berens now expects that the company will post earnings of ($4.03) per share for the year, up from their previous forecast of ($4.31). Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for OnKure Therapeutics’ current full-year earnings is ($4.05) per share. Leerink Partnrs also issued estimates for OnKure Therapeutics’ FY2026 earnings at ($3.05) EPS and FY2027 earnings at ($3.74) EPS.
A number of other equities analysts also recently issued reports on OKUR. Leerink Partners started coverage on OnKure Therapeutics in a research report on Thursday, December 5th. They set an “outperform” rating and a $33.00 price objective for the company. HC Wainwright restated a “buy” rating and set a $40.00 price target on shares of OnKure Therapeutics in a report on Friday, November 8th. Three research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $36.00.
OnKure Therapeutics Price Performance
Shares of OKUR opened at $5.45 on Monday. The stock’s 50-day moving average is $8.15. OnKure Therapeutics has a 12 month low of $4.57 and a 12 month high of $20.00. The firm has a market cap of $18.20 million, a P/E ratio of -0.45 and a beta of 0.25.
About OnKure Therapeutics
OnKure Therapeutics, Inc engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer.
Featured Stories
- Five stocks we like better than OnKure Therapeutics
- High Dividend REITs: Are They an Ideal Way to Diversify?
- META Stock: Insider Selling Ramps Up—What It Means for Investors
- What Are Dividend Champions? How to Invest in the Champions
- 3 Chip Stocks Still Trading 50% Below Their 52-Week Highs
- The How And Why of Investing in Oil Stocks
- U.S. Steel: Will Trump-Backed Nippon Investment Drive Upside?
Receive News & Ratings for OnKure Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OnKure Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
